Loading…
Loading…
ALLK (Allakos Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
ALLK does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ALLK and 80,000+ other tickers.
See exactly how ALLK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ALLK and 80,000+ other tickers.
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a…
NEW YORK , April 2, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Allakos Inc. (NASDAQ: ALLK ), relating to the proposed merger with Concentra Biosciences, LLC.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Allakos Inc. (NASDAQ: ALLK) to Concentra Biosciences, LLC for $0.33 in cash per share is fair to Allakos shareholders. Halper Sadeh encourages Allakos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Allakos and.
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Allakos will receive $0.33 in cash per each share of Allakos common stock. A.
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC ( “Concentra”) will acquire Allakos for $0.33 in cash per share of Allakos common stock (“Allakos Common Stock”).
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024.